1. Home
  2. IDE vs NBP Comparison

IDE vs NBP Comparison

Compare IDE & NBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Voya Infrastructure Industrials and Materials Fund of Beneficial Interest

IDE

Voya Infrastructure Industrials and Materials Fund of Beneficial Interest

HOLD

Current Price

$13.41

Market Cap

203.7M

Sector

Finance

ML Signal

HOLD

NBP

NovaBridge Biosciences American Depositary Shares

HOLD

Current Price

$1.77

Market Cap

225.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
IDE
NBP
Founded
2010
2014
Country
United States
United States
Employees
N/A
30
Industry
Finance/Investors Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
203.7M
225.5M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
IDE
NBP
Price
$13.41
$1.77
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$9.00
AVG Volume (30 Days)
29.1K
695.4K
Earning Date
01-01-0001
04-07-2026
Dividend Yield
8.83%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$11.36
$1.46
52 Week High
$14.30
$5.19

Technical Indicators

Market Signals
Indicator
IDE
NBP
Relative Strength Index (RSI) 42.59 46.17
Support Level $13.27 $1.67
Resistance Level $13.95 $1.95
Average True Range (ATR) 0.24 0.11
MACD -0.02 -0.01
Stochastic Oscillator 39.02 17.14

Price Performance

Historical Comparison
IDE
NBP

About IDE Voya Infrastructure Industrials and Materials Fund of Beneficial Interest

Voya Infrastructure, Industrials and Materials Fund is a diversified closed-end management investment company. The primary objective of this investment fund is to achieve total return by combining current income, capital gains, and capital appreciation. To achieve this objective, the fund invests in companies that own and/or operate infrastructure facilities in the infrastructure sector, as well as in a broad range of companies in the industrials and materials sectors that the Sub-Adviser believes will benefit from infrastructure building, renovation, expansion, and utilization.

About NBP NovaBridge Biosciences American Depositary Shares

NovaBridge Biosciences operates as a biotechnology platform, combining business development and clinical research to identify and advance pharmaceutical assets. Its inventive immuno-oncology pipeline consists of three clinical stage programs, givastomig; uliledlimab; and ragistomig. Its core product, givastomig, is a potential in-class CLDN18.2 bispecific antibody for the treatment of gastric cancer and other CLDN18.2-positive gastrointestinal malignancies.

Share on Social Networks: